Kaczorowski, M.; Lasota, J.; Dudek, K.; Małkiewicz, B.; Miettinen, M.; Hałoń, A.
Expression of Immunotherapy Target PRAME in Cancer Correlates with Histone H3 Acetylation and Is Unrelated to Expression of Methylating (DMNT3A/3B) and Demethylating (TET1) Enzymes. J. Clin. Med. 2024, 13, 1554.
https://doi.org/10.3390/jcm13061554
AMA Style
Kaczorowski M, Lasota J, Dudek K, Małkiewicz B, Miettinen M, Hałoń A.
Expression of Immunotherapy Target PRAME in Cancer Correlates with Histone H3 Acetylation and Is Unrelated to Expression of Methylating (DMNT3A/3B) and Demethylating (TET1) Enzymes. Journal of Clinical Medicine. 2024; 13(6):1554.
https://doi.org/10.3390/jcm13061554
Chicago/Turabian Style
Kaczorowski, Maciej, Jerzy Lasota, Krzysztof Dudek, Bartosz Małkiewicz, Markku Miettinen, and Agnieszka Hałoń.
2024. "Expression of Immunotherapy Target PRAME in Cancer Correlates with Histone H3 Acetylation and Is Unrelated to Expression of Methylating (DMNT3A/3B) and Demethylating (TET1) Enzymes" Journal of Clinical Medicine 13, no. 6: 1554.
https://doi.org/10.3390/jcm13061554
APA Style
Kaczorowski, M., Lasota, J., Dudek, K., Małkiewicz, B., Miettinen, M., & Hałoń, A.
(2024). Expression of Immunotherapy Target PRAME in Cancer Correlates with Histone H3 Acetylation and Is Unrelated to Expression of Methylating (DMNT3A/3B) and Demethylating (TET1) Enzymes. Journal of Clinical Medicine, 13(6), 1554.
https://doi.org/10.3390/jcm13061554
